In this interview, filmed at ASH 2018, Dr Robin Foà talks to touchONCOLOGY about recent developments in the treatment of haematological malignancies, namely the identification of new genetic abnormalities, the increase in chemotherapy-free treatments, and the use of molecular technologies to monitor minimal residual disease. 2018 has been an important year for immune therapies; checkpoint inhibitors have played an important role, and chimeric antigen receptor (CAR) T-cell therapy continues to develop. Looking to the future, Dr Foà suspects we will see the use of CAR T-cell therapy earlier in the disease course, and a reduction in the number of allogeneic stem cell transplant procedures. In terms of chronic lymphocytic leukaemia (CLL), we are seeing an increase in drugs that target pathways rather than genetic abnormalities, and combinations of novel agents. However, as developments continue to be made in the treatment of CLL, Dr Foà has concerns about how sustainable and accessible these drugs will be for the patients who need them.
1. What are the major unmet needs in the treatment of haematological malignancies? (0:10)
2. Following the influx of new therapeutics and the advent of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies, what role do you expect autologous and allogeneic stem cell transplantation to play in the future? (1:38)
3. Which new developments in haematological malignancies have excited you most in the past year? (3:54)
4. Will the management of chronic lymphocytic leukaemia change with the new data presented here at ASH 2018? (5:50)
Speaker disclosures: Robin Foà has nothing to disclose in relation to this interview.
Filmed at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, San Diego, CA, US, 1–4 December 2018
Share this Video
Related Videos In Haematological Malignancies
Shaji Kumar, ASCO 2021: The EQUATE Trial, a Quadruplet Regimen for Multiple Myeloma
We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab. The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended […]
Efstathios Kastritis, ASCO 2021: Results from the Phase 3 ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at ASCO 2021 to discuss the updated results from the phase 3 ANDROMEDA study. The abstract ‘Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results […]
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!